Product nameAnti-PPAR gamma antibody
See all PPAR gamma primary antibodies
DescriptionRabbit polyclonal to PPAR gamma
Tested applicationsSuitable for: ChIP, WBmore details
Species reactivityReacts with: Mouse, Human
Synthetic peptide corresponding to Human PPAR gamma (internal sequence) conjugated to keyhole limpet haemocyanin.
Database link: P37231
- ChIP: Chromatin prepared from macrophages derived from mouse bone marrow. WB: pNTAP-PPAR gamma transfected HEK-293T cell extract.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservatives: 0.05% Sodium azide, 0.05% Proclin
Concentration information loading...
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Fatty acids
Our Abpromise guarantee covers the use of ab233218 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ChIP||Use at an assay dependent concentration.
Use 1 µg/ChIP reaction.
|WB||1/2000. Predicted molecular weight: 57 kDa.|
FunctionReceptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
Tissue specificityHighest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
Involvement in diseaseNote=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
Sequence similaritiesBelongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
- Information by UniProt
- CIMT1 antibody
- GLM1 antibody
- NR1C3 antibody
All lanes : Anti-PPAR gamma antibody (ab233218) at 1/2000 dilution
Lane 1 : pNTAP-PPAR gamma transfected HEK-239T (Human epithelial cell line from embryonic kidney transformed with large T antigen) protein extracts
Lane 2 : Non-transfected HEK-239T (Human epithelial cell line from embryonic kidney transformed with large T antigen) protein extracts
Lysates/proteins at 20 µg per lane.
Predicted band size: 57 kDa
Dilution buffer: TBS-Tween containing 3% skimmed milk.
ChIP was performed on macrophages derived from mouse bone marrow using ab233218 and optimized PCR primer sets for qPCR. Sheared chromatin from 1 million cells and 1 µg ab233218 were used per ChIP experiment. IgG was used as a negative IP control.
Recovery, expressed as the % of input, of the PDK4 PPAR response element (RE).
ChIP was performed on macrophages derived from mouse bone marrow using ab233218 and optimized PCR primer sets for qPCR. Sheared chromatin from 1 million cells and 1 µg of PPARg antibody were used per ChIP experiment. IgG was used as a negative IP control.
Recovery of the FABP4 Adipo PPAR RE in cells treated with RSG, a very strong activating ligand of PPARG, and in untreated cells.
ab233218 has not yet been referenced specifically in any publications.